Hepatocellular carcinoma (HCC) is the third leading cause of cancer death worldwide.
Surveillance for HCC is critical for early detection and treatment, but fewer than one-quarter …

The burden of hepatocellular carcinoma (HCC) is highest in East Asia and Africa, although
its incidence and mortality are rapidly rising in the United States and Europe. With the …

Background & Aims It is unclear whether direct-acting antiviral (DAA) treatment-induced
sustained virologic response (SVR) reduces the risk of hepatocellular carcinoma (HCC) in …

Hepatocellular cancer (HCC) is the fourth leading cause of cancer-related deaths worldwide
and the fastest growing cause of cancer deaths in the United States. The overall prognosis …

Background & Aims It is unclear if hepatocellular carcinoma (HCC) risk declines over time
after hepatitis C virus (HCV) eradication. We analyzed changes in HCC annual incidence …

Background and Aims Hepatocellular carcinoma (HCC) surveillance is associated with early
tumor detection and improved survival; however, it is often underused in clinical practice. We …

Background & Aims Hepatocellular carcinoma (HCC) can develop in individuals without
cirrhosis. We investigated risk factors for development of HCC in the absence of cirrhosis in …

Sustained virologic response (SVR) after direct acting antiviral agents (DAAs) holds promise
for reducing hepatocellular cancer (HCC). DAAs have recently been available long enough …

The epidemiology of hepatocellular carcinoma (HCC) is characterized by dynamic temporal
trends, several major established (ie, HCV, HBV, alcohol) and emerging (ie, diabetes …

Background & Aims Cirrhosis and hepatocellular carcinoma (HCC) are predicted to increase
in the United States but the accuracy of prior forecasts and the contributions from various …